Inhibition of KCs suppresses hepatic steatosis, indicating that activation of KCs plays a crucial role in non-alcoholic fatty liver disease pathogenesis and progression (Huang et al., 2010[17]). Here, TBCE is linked to metabolic dysfunction-associated steatotic liver disease.